small molecule glp 1 agonist Figure from Drug Discovery at the Glucagon-Like Peptide-1 Receptor The challenge of developing oral
Description
FDA is acknowledging that the drugs dont have the same risk seen with older weight-loss medicines
Insurance coverage semaglutide often has broader approval

Most Phase 1 obesity trials run against placebo and let cross-trial comparisons sort out the relative efficacy

Screening for infective causes should be done in anyone with acute diarrhoea plus indicators of infection (fever, systemic symptoms, recent travel or infectious contact)

however, they wondered whether GLP-1 was more interesting than the already known incretin GIP, which exhibited a diminished effect on insulin secretion in patients with T2D (36)

Additionally, SGLT2is have demonstrated beneficial effects on MASLD, showing histologically proven improvements in hepatic steatosis, inflammation, and fibrosis 6,7,8
